Rejuvenate Biomed is a biomedical company researching the biology of aging and applying this knowledge to identify safe and well tolerated drugs that maintain and restore our natural cell resilience capacity delaying age-related functional decline.
Welcome at Rejuvenate Biomed
We envision a future where people stay healthy for life.
Biology of aging
Major progress has been made in the biology of aging also known as geroscience. This has resulted in a better scientific understanding of the biological processes associated with age-related functional decline. Several mechanisms have been elucidated and drugable targets have been identified.
We identify opportunities to impact the aging process by repositioning Rx products. Our portfolio currently contains 7 compounds, selected via our Pre-Clinical and Clinical platforms focusing on safety and their efficacy potential. We are preparing our lead candidate for a POC study, starting in 2020.
Lead compound RJX01
Our lead candidate RJX01, and first entry into market, is a combination product indicated to treat Sarcopenia. Sarcopenia is the progressive loss of skeletal muscle mass and strength. It affects 10% of the overall population, and 50% of 80 year old. It increases the risk of physical disability, poor quality of life and death.